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Ketamine administration in sub-dissociative doses in the emergency department (ED) results in 
effective pain relief in patients with acute traumatic and non-traumatic pain, chronic pain, and opioid-
tolerant pain. This case series describes five adult ED patients who received nebulized ketamine for 
predominantly acute traumatic pain. Three patients received nebulized ketamine at 1.5 milligrams 
per kilogram (mg /kg) dose, one patient at 0.75 mg/kg, and one patient at 1 mg/kg. All five patients 
experienced a decrease in pain from the baseline up to 120 minutes. The inhalation route of 
ketamine delivery via breath-actuated nebulizer may have utility for managing pain in the ED. [Clin 
Pract Cases Emerg Med. 2020;4(1):X–X.]   
INTRODUCTION
Ketamine is a non-competitive N-methyl-D-aspartate/
glutamate receptor complex antagonist that decreases pain by 
diminishing central sensitization, hyperalgesia, and “wind-up” 
phenomenon at the level of the spinal cord (dorsal ganglion) 
and central nervous system.1 Ketamine administration in sub-
dissociative (SDK) dose (0.1–0.3 milligrams per kilogram (mg/
kg)) in the emergency department (ED) results in effective pain 
relief in patients with acute traumatic and non-traumatic pain, 
chronic non-cancer and cancer pain, and opioid-tolerant pain by 
virtue of providing anti-hyperalgesia, anti-allodynia, and anti-
tolerance.2,3 Two commonly employed administration strategies 
of SDK administration in the ED include an intravenous (IV) 
route (push-dose, short infusion, or continuous infusion), and 
intranasal route.4,5 However, in situations when IV access is 
unobtainable and /or mucosal atomization device is not readily 
available, nebulized routes of analgesic administration can be 
used. The nebulization of analgesics in the ED provides rapid, 
effective, and titratable analgesic delivery. It also results in less 
painful methods of analgesic delivery, minimizes analgesic 
toxicity and side effects (for example-opioids), and improves 
overall management of a variety of painful conditions in the ED.6
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Nebulized administration of ketamine has been studied 
in the areas of palliative care, therapy for asthma, and 
acute postoperative management of sore throat.7-9 To our 
knowledge, there is no literature regarding analgesic efficacy 
and safety of nebulized ketamine’s role in managing acute 
painful conditions in the ED.The following cases describe 
five patients presenting to the ED of a tertiary medical center 
between May-June 2019 with acute painful conditions 
and receiving nebulized ketamine at three different dosing 
regimens of 0.75 mg/kg, 1 mg/kg, and 1.5 mg/kg via breath-
actuated nebulizer. 
CASE SERIES
We describe five patients, ages 30-54, who presented to the 
ED with acute painful conditions: four patients with traumatic 
musculoskeletal pain, and one with abdominal pain (Table 1). 
Case #1 
A 44-year-old man without prior medical history 
presented to the ED with one-day history of traumatic injury 
to his right wrist and hand with severe 8/10 pain and moderate 
swelling along the dorsal aspect of the right hand and wrist. 
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What do we already know about this clinical 
entity? 
Ketamine is used in the emergency 
department (ED) via intravenous, 
subcutaneous, and intranasal routes for 
managing acute painful conditions.
What makes this presentation of disease 
reportable? 
This is the first description of the use of 
ketamine analgesia via breath-actuated 
nebulizer for adult ED patients presenting 
with acute painful conditions.
What is the major learning point? 
Nebulized ketamine at doses of 0.75 milligrams 
per kilogram (mg/kg), 1 mg/kg, and 1.5 mg/kg 
alleviates acute pain in adult ED patients.
How might this improve emergency 
medicine practice? 
Ketamine administration via breath-
actuated nebulizer may serve as an 
additional non-invasive route for delivering 
analgesia in the ED.
Radiographs were negative for acute fracture or dislocation. 
The patient received only two doses of nebulized ketamine 
at 0.75 mg/kg with change in pain score from eight at the 
baseline to one at 120 minutes (min) (Table 2). The patient 
was discharged with a final diagnosis of wrist strain. 
Case #2 
A 43-year-old woman without prior medical history 
presented to the ED with a chief complaint of 8/10 severe 
bilateral knee pain over the prior six months with pain radiating 
to both of her calf muscles and associated with stiffness. On 
physical examination the patient had moderate right patellar 
tenderness, no appreciable joint effusion, and no evidence of 
infectious/inflammatory processes. She received a single dose 
of nebulized ketamine at 1 mg/kg with a change in pain score 
from eight at baseline to zero at 120 min (Table 2). The patient 
was discharged with a final diagnosis of traumatic knee pain.
Case #3 
A 30-year-old man without prior medical history presented 
to the ED with severe, 8/10 pain to his left hand after slamming 
it with a car door. On examination, the patient was noted to 
have swelling and tenderness to palpation at the dorsal aspect 
of the left hand/metacarpal region with decreased range of 
motion at the second through fifth metacarpal joints and intact 
neurovascular status. He received nebulized ketamine at 1.5 mg/
kg with change in pain score from eight at the baseline to two 
at 120 min (Table 2). The patient was discharged with a final 
diagnosis of hand contusion.
Case #4 
A 54-year-old man without prior medical history presented 
to the ED with severe, 9/10 acute lower back pain after a fall 
at home that resulted in the patient landing on his back and 
Patient 
number
Age/
sex
Chief 
complaint Weight
Dosing mg/kg 
- actual dosea
Doses 
given
Total dose 
receivedb
Baseline vital signs
HR BP RR SpO2
1 44M Traumatic 
arm pain
70 kg 0.75 mg/kg – 
55mg
2 55 mg 88 140/93 20 99
2 43F Traumatic 
knee pain
67 kg 1.0 mg/kg – 
65 mg
1 19.5 mg 78 112/58 16 100
3 30M Traumatic 
arm pain
90 kg 1.5 mg/kg – 
135 mg
1 108 mg 83 131/98 13 100
4 54M Traumatic 
back pain
70 kg 1.5 mg/kg – 
105 mg
1 105 mg 61 121/71 14 98
5 38F Abdominal 
pain
65 kg 1.5 mg/kg – 
100 mg
2 140 mg 72 116/72 15 97
Table 1. Characteristics of patients given nebulized ketamine.
a Actual dose: Indicates the per dose concentration the patient was meant to receive.
b Total dose received: Indicates the total amount a patient consumed after wastage.
M, male; F, female; kg, kilogram; mg, milligram; HR, heart rate; BP, blood pressure; RR, respiratory rate; SpO2, peripheral capillary 
oxygen saturation.
subsequently sliding down 10 steps. On examination, he had 
prominent paraspinal tenderness at the lumbar region without 
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swelling, ecchymosis, or laceration. He received nebulized 
ketamine at 1.5 mg/kg with change in pain score from nine 
at the baseline to zero at 120 min (Table 2). The patient was 
discharged with a final diagnosis of traumatic back pain. 
Case #5 
A 38-year-old woman without prior medical history 
presented to the ED with chief complaint of severe 9/10 
crampy abdominal pain and nausea and single episode of 
loose stool. On examination, the patient had prominent 
epigastric and periumbilical tenderness without rebound 
and guarding. She received IV famotidine and ketorolac 
without appreciable pain relief and subsequently received 
two doses of nebulized ketamine at 1.5 mg/kg with change 
in pain score from nine at the baseline to zero at 120 min 
(Table 2). The patient was discharged with a final diagnosis 
of viral gastroenteritis.
Three patients were male and two were female. None of 
the patients had absolute contraindications to ketamine such 
as allergy to ketamine, pregnancy, or history of schizophrenia. 
We used a standard verbal numeric pain-rating scale to 
evaluate patients’ pain scores at the baseline and at 15, 30, 
60, 90, and 120 min.10 We used the Side-effects Rating Scale 
of Dissociative Anesthetics to describe side effects related to 
ketamine administration from baseline to 120 min.11
Three patients received nebulized ketamine via breath-
actuated nebulizer at 1.5 mg /kg dose, one patient at 0.75 
mg/kg, and one patient at 1 mg/kg. Two patients requested 
and received a second dose of nebulized ketamine. The 
dosages of nebulized ketamine (ordered and received) as 
well as baseline vital signs are presented in Tables 1 and 
2. All five patients experienced a decrease in pain from 
baseline to 15 min, 30 min, 60 min, 90 min, and 120 min 
post medication administration (Table 2). 
One patient experienced dizziness of modest intensity 
that was self-limited after 60 min and felt fatigued at 90 min. 
Another patient experienced a mood change, self-described as 
feeling “relaxed and happy,” at 15 min (Table 3). No patient 
experienced elevated heart rate and/or blood pressure during 
the observational period.
DISCUSSION
In situations when intravenous access and /or mucosal 
atomization devices are not readily available, inhalation 
(nebulization) route might be considered for provision of 
timely and effective analgesia in the ED. However, safety and 
efficacy of ketamine in a nebulized form as an analgesic in the 
ED setting has yet to be shown. 
Nebulized administration of ketamine has been studied 
in the areas of palliative care, asthma therapy, and acute 
postoperative management of sore throat.7-9,12,13 Five 
randomized trials have compared nebulized ketamine either in 
a fixed-dosing regimen (50 mg) or weight-based dosing (0.5 
mg/kg, 1mg/kg, or 1.5 mg/kg) to placebo in reducing post-
intubational sore throat. The average decrease of postoperative 
throat pain decreased by 44-50% without any major side 
effects.7-9, 12,13 Similarly, ketamine inhalation in healthy 
volunteers was easily tolerated and was not associated with 
oropharyngeal irritation, hypersalivation, stridor, laryngospasm, 
cough, dry mouth, hoarseness, dyspnea, tachypnea, aspiration, 
cardiac dysrhythmias, or desaturations.14,15
Pharmacokinetic properties of inhaled ketamine have 
not been studied broadly, but a single observational study 
evaluated pharmacokinetics of S-ketamine administered via 
nebulization to 12 healthy volunteers at doses of 0.35, 0.5, and 
0.7mg/kg and inhalation duration of 20–40 min. The study 
demonstrated a time to maximum concentration of 15-22 min 
and a maximum concentration of 128ng/ml.15   
In addition, based on the bioavailability of intranasal 
ketamine (25-50%) and oral ketamine (16-24%), the 
bioavailability to nebulized ketamine ranges between 20-40% 
of IV route.16,17  To date, this case series is the first to describe 
the use of nebulized ketamine via breath-actuated nebulizer 
at three different dosing regimens, with titration as needed for 
patients presenting to the ED with acute traumatic and non-
traumatic painful conditions. The breath-actuated nebulizer 
(BAN) (AeroEclipse, Trudell Medical International, London, 
Ontario, Canada) provides smaller particles and greater dose 
delivery efficiency than continuous jet nebulizers. In addition, 
BAN possesses dual modes of action: 1) continuous aerosol 
generation; and 2) breath-actuated (in response to the patient’s 
Patient number
NRS pain over time
Baseline 15 min 30 min 60 min 90 min 120 min
1 8 6 5 5 1 1
2 8 5 3 2 0 0
3 8 5 4 2 2 2
4 9 6 4 0 0 0
5 9 2 2 1 1 0
Table 2. Numerical pain scores.
NRS, numeric pain-rating scale; min, minutes.
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inspiratory flow), ensuring that virtually no drug is lost to the 
environment.18,19 Furthermore, BAN has a potential to provide 
greater compliance and safer patient environment that may 
impact overall pain management, patients satisfaction, and 
length of stay in the ED.
All five patients had a decrease in pain from the baseline 
to 120 min with average change in pain score of 3.6 at 15 min, 
4.6 at 30 min, 6.4 at 60 min, 7.6 at 90 min, and 7.8 at 120 min. 
Furthermore, only one patient experienced dizziness of modest 
intensity. While the descriptive nature of this report cannot be 
used to make any conclusion of safety and efficacy of nebulized 
ketamine in managing pain in the ED, the non-invasive route, 
titratability, and self-administration (by the patient) make this 
analgesic modality an attractive choice, especially when IV 
access is not readily available or unobtainable. There is a need 
for larger, dose-finding studies in a prospective, randomized 
fashion to fully evaluate the safety and efficacy of nebulized 
ketamine for analgesia in the ED. 
CONCLUSION
The inhalation route of ketamine delivery via breath-actuated 
nebulizer for managing pain in the ED may add an additional 
modality to the analgesic armamentarium of ED clinicians in 
providing rapid, effective, and non-invasive pain relief. 
Adverse effect Time point Level of severity
1-Weak 2-Modest 3-Bothersome 4-Very bothersome
Dizziness
15 min -- Patient 2 -- --
30 min -- Patient 2 -- --
60 min -- Patient 2 -- --
90 min -- -- -- --
120 min -- -- -- --
Fatigue
15 min -- -- -- --
30 min -- -- --
60 min -- -- -- --
90 min -- Patient 2 -- --
120 min -- -- -- --
Mood change
15 min Patient 3 -- -- --
30 min -- -- -- --
60 min -- -- -- --
90 min -- -- -- --
120 min -- -- -- --
Table 3.  Severity of side effects using rating scale of dissociative anesthetics by patient and time.
min, minutes.
Documented patient informed consent and/or Institutional Review 
Board approval has been obtained and filed for publication of this 
case report.
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